Miglitol: Difference between revisions
m Protected "Miglitol": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
{{drugbox | {{drugbox | ||
| Line 41: | Line 41: | ||
{{oral hypoglycemics}} | {{oral hypoglycemics}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Alpha-glucosidase inhibitors]] | [[Category:Alpha-glucosidase inhibitors]] | ||
Revision as of 17:26, 9 August 2012
| Error creating thumbnail: File missing | |
| Clinical data | |
|---|---|
| [[Regulation of therapeutic goods |Template:Engvar data]] | |
| Pregnancy category | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Dose-dependent |
| Protein binding | Negligible (<4.0%) |
| Metabolism | Nil |
| Elimination half-life | 2 hours |
| Excretion | Renal (95%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C8H17NO5 |
| Molar mass | 207.224 g/mol |
|
WikiDoc Resources for Miglitol |
|
Articles |
|---|
|
Most recent articles on Miglitol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Miglitol at Clinical Trials.gov Clinical Trials on Miglitol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Miglitol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Miglitol Risk calculators and risk factors for Miglitol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Miglitol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
For patient information, click here
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
See also
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Endocrinology
- Alpha-glucosidase inhibitors